Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glycolytic shift during West Nile virus infection provides new therapeutic opportunities

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE233218 | GEO | 2023/09/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Glycolytic shift during West Nile virus infection provides new therapeutic opportunities [Cerebellum]

Project description:To investigate the in vivo metabolic changes during WNV infection in a mouse model, we infected mice with WNV NY99 to compare to uninfected (mock) mice. We also use two compounds targeting energetic metabolism to analysed their effects on WNV infection We then performed gene expression profiling analysis using data obtained from RNA-seq from infected vs uninfected mice and treated mice.

2023-09-27 | GSE233217 | GEO

Glycolytic shift during West Nile virus infection provides new therapeutic opportunities [Brain]

2023-09-27 | GSE233216 | GEO

Glycolytic shift during West Nile virus infection provides new therapeutic opportunities [2DG and DGA compounds]

Project description:To investigate the in vivo metabolic changes during WNV infection in a mouse model, we infected mice with WNV NY99 to compare to uninfected (mock) mice. We also use two compounds targeting energetic metabolism to analyze their effects on WNV infection We then performed gene expression profiling analysis using data obtained from RNA-seq from infected vs uninfected mice and treated mice.

2023-09-27 | GSE233215 | GEO

A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes.

Project description:Defining the precise cellular mechanisms of neutralization by potently inhibitory antibodies is important for understanding how the immune system successfully limits viral infections. We recently described a potently inhibitory monoclonal antibody (MAb E16) against the envelope (E) protein of West Nile virus (WNV) that neutralizes infection even after virus has spread to the central nervous system. Herein, we define its mechanism of inhibition. E16 blocks infection primarily at a post-attachment step as antibody-opsonized WNV enters permissive cells but cannot escape from endocytic compartments. These cellular experiments suggest that E16 blocks the acid-catalyzed fusion step that is required for nucleocapsid entry into the cytoplasm. Indeed, E16 directly inhibits fusion of WNV with liposomes. Additionally, low-pH exposure of E16-WNV complexes in the absence of target membranes did not fully inactivate infectious virus, further suggesting that E16 prevents a structural transition required for fusion. Thus, a strongly neutralizing anti-WNV MAb with therapeutic potential is potently inhibitory because it blocks viral fusion and thereby promotes clearance by delivering virus to the lysosome for destruction.

| S-EPMC2679195 | biostudies-other

New insights into innate immune restriction of West Nile virus infection.

Project description:West Nile virus (WNV) is an encephalitic flavivirus that has provided a valuable experimental system for studying viral pathogenesis and immunity. Although in vitro approaches and mouse models of infection have identified pattern recognition receptor and interferon pathways that control WNV infection, our appreciation of specific antiviral effectors has been more limited. In this review, we highlight recent advances in our understanding of the host factors that restrict WNV infection in mammals and insects, especially those resulting from large-scale screening approaches.

| S-EPMC4456296 | biostudies-literature

A Mouse Model of Chronic West Nile Virus Infection

Project description:Here, we characterize the RIX line CC(032x013)F1, which serves as a mouse model of chronic WNV infection. While studies using C57BL/6 mice have shown that WNV RNA can persist in the CNS up to 3 months post infection in a limited fraction of mice (Appler et al., 2010), to date there is a lack of a robust mouse model of chronic West Nile virus infection that can be used to elucidate the immune responses associated with this viral persistence and chronicity of symptoms described in human patients. Here, we characterize this line in comparison with lines showing either no disease symptoms or significant disease, and suggest a mechanism by which WNV infection can become chronic through alterations in immune responses.

2016-06-01 | GSE82046 | GEO